Oxford BioMedica, a UK-based, clinical stage biotech company, is a global leader in the exciting and rapidly advancing field of gene and cell therapy. They have their own portfolio of pre-clinical and clinical-stage product candidates and also have licensed technology and provide revenue-generating services to third parties, most notably Novartis. Novartis’s CTL019, a breakthrough therapy for leukaemia, may reach the market by year-end.
23 Mar 2017
Oxford Biomedica - Leading Gene Delivery Platform
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Oxford Biomedica - Leading Gene Delivery Platform
Oxford BioMedica plc (OXB:LON) | 201 7.7 1.9% | Mkt Cap: 201.3m
- Published:
23 Mar 2017 -
Author:
Dr. Riccardo Lowi -
Pages:
4
Oxford BioMedica, a UK-based, clinical stage biotech company, is a global leader in the exciting and rapidly advancing field of gene and cell therapy. They have their own portfolio of pre-clinical and clinical-stage product candidates and also have licensed technology and provide revenue-generating services to third parties, most notably Novartis. Novartis’s CTL019, a breakthrough therapy for leukaemia, may reach the market by year-end.